REGISTERED COMPANY NUMBER: 08116159 {England and Wales) REGISTERED CHARITY NUMBER.. 1148845 TRUSTEES. REPORT AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2024 FOR ALEX'S WISH (A COMPANY UMITED BY GUARAp¥fEEI StunJess Hutchinsc Chartered Certif*d Account8nts 21 New Walk Leicesier LE16TE
ALEX'S WISH CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2024 R•f•r•ne• and Admlnl$tratlv• D•tall$ Tru8t••s' Report 2 to 12 Indondnt Examln•rf¥ R•port 13 Stat•m•nt of Flnanclal Actlvltl•s 14 Balanc• 8h••l 15 Not•• to th• Fln•n¢lal Statsm•nts 16 to 19 D•t•ll•d Stat•m•nt of Flnanclal Actlvltl•s 20 to 21
ALEX'S WISH REFERENCE AND ADMINISTRATP4E DETAILS FOR THE YEAR ENDED 30 JUNE 2024 Ms S L Bamett Iresigned 1716120241 Mr T W Carter {resnlI 1110120231 Ms J Etfvrnrds (resigned 1716r20241 Mr C R Everard Mrs E J Hallam Mr A R Hallam Ms A L Slack Mr S Jesrani Ms G Wright Ms A K Iqbal {8ppointed 114120241 Mr W Hazlèngg lappointed 912120241 R•g5st•r•d offie• 21 New Walk L8i¢èstsr LE1 6TE R•gl8t•r•d company numb•r 08116159 (England and Wales) R•gl•t•r•d charlty numb•r 1148845 Ind•p•nd•nt •xamln•r StunJe88 Hutchin Chartered Ceitified Ac¢ountsnts 21 New Walk L8i¢e$ter LE1 6TE W•b•lt• ¥wM.alex*A8h.co.uk 8ank•rn Natnl Westminster Bank 5 The Parade Oadby Leicesler LE2 5NT
ALEX'S WISH TRUSTEES. REPORT FOR THE YEAR ENDED 30 JUNE 2024 The Trustoes, who are 81s0 Dir¢ctOfS of the ¢haritsblè company for the purposes ol th& Companies Act 2006. presonl their r8port Mih the financial statements of the charity for the year ended 30 June 2024. The tnjstees have adopted the provisons of Acctsunting and Reportiro by Chariles.' statement of Recommended Prdctice applicable to charib'es preparing their accounts in accordance ¥wih the Financial Rewrbng StsrK18ftl applicab in UK and Rèpublic of Ireland IFRS 10211offgCtive 1 J8nuary 20191. Sclentlfic Advlsory Board We work closely wth Duchenne UK as their Charity Partner and as such, m05t projects thal fvnd are co-funded alongside them. All projects put forward to us for potential fundin9 go thrcwh thelr iigonws Scienlific Adwsory Board, vknich Is made up of some of tha wodd's lèading exp6rts in Duchonne Muscular ttyslrophy. They bring wilh them a %wle rnnge of e888nlial skills and knovw basos, including entIfic, dinieAI 8nd drug discovery and development. When soienlists corne forward wth IheTrr id6a$ lor nsw rèsearch projè¢ts. it 1$ this board who apply their trxperi8ncè and expertise to tesl thèse idèas. h&lpin9 iefine them. if ne$sary, in order that we can make inlomed declsions on fvnding. We want to lund great science and preCtS that can improve our knovA8dge base. ireaiments thal can reach thg cllnic and irnprove the lives of p8Oe wth Lhjchenne. Du¢h8nn& VK'8 8dvisory board ¢onws¢$ ofr. Professor Dame Kay Dawe8 Dr. John Bourke Dr. Dada Pisconti Dr. Val&ria Ricottl Professor Giovannl Baran8lkJ Professor Jordi Oiaz Manera Dr. Tina Duong Dr. Isabellg Rl¢hard Dr. Carina Schoy Professor Francesco Saverlo TedeBeO Dr. Graeme Wilkinson Algx's Wish would Ilko to thank its Twstegs, employees. 80th prowders and supporters for kindly glvlng ih•lr tlm8 and axportise to grow the charity. StOt•m•nt from th• CEO and Charlty Found•r. Emma Hallam Sln¢& wg launched Alex's Wish In late 2012. after our son Alex was diagno8ed Duchenne Muscular Dystrophy - we hav8 made great progress Iow8rd$ bringing effective new treatmenls lo help ry0fiè affgctod by this d¢sèasg, 8$ well as helping to improve care stsndar(1s across the UK - 11$1 also suppor"Tha new 18¢hnolcgi¢al advan¢oS to help improve qu81ity of life foi 8varyone1Sving wlth Duchenne. We would Ilke to thank èveryone has Supported us to dale. we could not do wh81 we do with out you. Thank you from the bottom of my heart. Background to ¥9tt5ng up A.& Wlsh Ouchenne is a life-changer. 118ffects every sirKJle d8y of your Irfo as you must be prepa0 for evor-changing challenges that affe¢t your child'slyoung adult's day to day athitsès. Ouchenne is a prc>assIVe, musde wastiThJ diseas8. 11 is rèlantlass, affecting every sitvJle muscle in the body. One day your chikl may not be able to walk, may not be able to lift a cup to their mouth, may not be able to access their In'ends. homes anymore. We fett oveThthelmed and terrifièd of vth8t the future held for our son, living in fear of the noxt Stage of pwression and M)ndorgd ¥)Uld eop8. At the time of diagnosss, we quickly alISed we had no time to waste. and that fvndirJ was the rnain cause of concem. So, we set.up Alex's Wish. a charity based in the heart of Leicestershire, as knew would 8ttr8cI Interest and support from the ornmunily across the East Midlands and boyond, bn"ngirw3 in additional funds to vthat was aladY b&ing rais8d. Wg do not duplicale gfforts of other charities working in this field. instead our focus is to drive additional funds, allowng us to ¢fild projects wth other charities like Duchenne UK. An excltlng tlme In medlcal breakthroughs Thè sciènce is at a very exciting time- a time of opts'mism as new treatrnenls are now ernergiryJ to delay disease progression. We are acutely aware ihat time is not on our side, and that for f8milies affeded by Duchenne whelher they have a child diagnosed several years ago. or rtew families r8ceivin9 a r*cÈnt di8gno&s- naed solutions to support their child. This is what drives us evgry singl$ day, to fundraise and rnise awareness to conb.nue SUP[rlIng new innovative projects to address the problems vthhin the thjchenne community.
ALEX'S IMSH TRUSTEES. REPORT FOR THE YEAR ENOED 30 JUNE 2024 Vamorolon6 In 2023, we saw a bre8kthrowJh - the first ever dnjg approved for use on chiklren Duchenne - called Vamorolone. It is r&aching patients bècausè charities liké ours help to fund the earty stages of the project. Whèn Alèx was di89nosed back in 2010, wefe toh1 the standard medication for children wth Duchenne. steroids, wyjuld keep them indèpendently mobile for longer, bul wth hamiful side effects. The resgarch w8 have funded is now bearing Iwit. Varnordone a new sleroid drug, thal has less hamiful Sdeoffects to tradits.onal steroids, has now been approved by the Medicines and He3care products Regulatory Agency IMHR41 in the UK. We are incredibly proud that we were able lo invest in the Èarty stages tts make this a reality- proof that Algx's Wish is a charity that is rnakiThJ a posib've irnp for this general ofchildren and yotsng adults Imng Duchenn8. Gene Th•rapy We wère told that Gen8 Th&rnpy x)uldnl hapk)gn in our son's lth'm8. During th& tim¥ that Al8$ Wish h88 been in operation. we supported Solid Biosciences, a start-up to pursue this rrf technology. and boys a now being dosèd with gtrn8 therapy in clinical trials takiro place now in Ihe UK. We know there are challenges Gene Therapy, bthich is why arg continuing 8UPPOrt projects that are looking to address these prob18m6. and brirrfJ better therapies to our children. Innovatl¥• technolog1•8 Supportiro Duchenne UK, afe helpiThJ driv6 technological advances for the ben6fit ol chiklfen and young advlls living with Duchenne. We are supporting a project to help devety the fit ever ami assist device (called ELEVEXI to support ami lunclion. It is a project that puls the needs and aspirations of Ovchenne chibdren al its heart. %ith ihe potenlial to bring benefit to other pgople with arm rnobilrty issues. In atjdilion, are supwmting The DREAM Wheetchair projecl . again working alongside Duchennè UK. These probocts aim to brirvJ bett8r quality ol lifg to overyone affocled by Duchonn8 8nd we 8r6 8XClted wth the progress being made. B•8t practlc• In Ouch•nn• car• Wè orè working alongside DMD Care UK. to help 8UPPOrt better qualty of caro for everyme liviThJ wlh Duch8nn8 in the UK. To dale, we have fund•d projects, including financial support for a OMD Hub Pmlect Managar designgd to incffjase clinlc81 tri81 capacity in the UK, a nutrition programme supporting those affected by Duchenne. and a research project looking to add8$ the 18ck of a¢¢essibl8 housino amongst our community. Al the limtt ol tiftg this report. we h8ve funded additional care projècts - including a transition proje¢l, lo h&lp those IransibonirYJ from paedialric care into adulthood something which we have Tecenily encountered rwjrnelves ith Aax. With all lhis progress. we cannot help bul leel irKredibly optimistic Ihat rnore effective treatments wll ernerge, and new Innov81ive technologies 11 b8com& available alongside improve(1 care standards to help everyone livin9 Wth Duchenne. The hard work is paying off, must ¢ontinug our ioumèy and fvnd the projects already invested in to get those lo the nexl siages, as well as find new discoveries to slow down and uttimatety stop muscle wastsrrfJ. Our mSsslon is not only lo er8dicate Duchenne. but to slow do¥ Ihe disease and help those living wth Duchenn8 live the best lives posslble vlth new 18chnologlè8 and improve(1 stsndards of caffj. We are delighted wsih our progress io dale and exciied abrrtrt the times ahead. We are incredibly grateful to our wondgrful supporters who have come on this joumey us so far. We are Incredibly positiv& aboul thè future and Af•x's Wlsh gtves us hope. Duchenne Muscular Dystrophy Is part of oui liv88, not out ol choice, but we wll make il as besl as can, and we wll never stop ourloumey lo conquering Duchgnne. I conllnue to 8UPPOrt lo this important cause, by voluntsrity ts the ¢hartty and a vory proud trustee and CEO- it is rny pl8asLtre to do thls. to support all familios affected by thjchenne. Wè Could nol havo done our work wilhoul our army of SUPkX)rters, the charilable foundations who have supported us, the local busin&ss community, our busine$s sponsors. our fundraising 10am. ambassadors and our dedi¢aled truslees and we would like to express our gratitude and thanks to every single one of them. Bast wshes, Emma Hallam Charity Fourbder Our Vi8lon Our Visson is a worfd wtholrt tJChen Mus£ular Dystrophy. We want a lutui• that stops the devastating impact t)uchgnne ha$ on our thiklwi and young adults. a Itrture where they can grow and prosper and fu1 their dreams. A life vthere they can enjoy every day thl the fear of the FKc*Jres8i this fflu Wdsting disease has on Iheir bodies. A fvture wthout Ducher¢ne would be a tryht and happy fiJtUTe for all those affected.
ALEX'S WISH TRUSTEES. REPORT FOR THE YEAR ENDED 30 JUNE 2024 We need to act quickly to save this generation. Doing nothing is not an opb'on. Our iws and their families nead lo live wthout fear and have hope for the firturs. Our MIs8Son AJ8x's Wish has one dear aim- to conquer ThKhenne frythi$ 98nerJtion. Together ill end Duchonng. Oui ultimate focus is to exteftd the lives of those liwr¥J wAth thJchènn¢ right now. lo halt and ultimately reverse the effecis of mu8cle wasting. Whilst also suppoth"rwJ the delivery of excellent slaThJards of care and nèw technosogies to help improv& the live8 of Ih05e affected in the UK. Alex's Wish was s&l-up by a famity affected by Duchenne. Lmderstsnd firsl-hand the impaci this condltion ha8 on their chi and the family. As a lamily WÈ are takir¥ part in clinical trials oUrSeeS as V•e undgts18nd Ihe smportance of clinical tri818 and how they will help bring effectivè tr&atmènls to market. Alex, who Inspir&il u$ lo create this chaiity. has spent 11 years of his life so far on clinical tsials, and has help8d in his way lo brlng about a new Irealmenl called Giwnoslal to markel- a drug Ihal is proven to delay disease progression in Duchenne. We are so proud ol the efforts ho puls in to support our fundraising activTrts6s. Charilles like ours lund haw of all medical S81¢h in the UK lo the lune of £1.7bn. Today. 1 in 4 people choose lo support medical rèsearch ¢h8rities like ourn. and lor Ihis afe so incredibly gratelul. Our Impact The Trustees are d81ighied that ihey hava Wn able lo m8ke Significant payThents during Ihls accountancy perfod lo fvvo prolècts gqualing 10 £113,000 in line its obj¢ctiv¢$. We provide projecl updales as and thay become available on our w8bsite alox$wish.¢o.uk, e-newsletters to rwjr supporters and al our events - namely our Aulumn Lun¢h and Spring Launch events. Gl¥•n an addltlonal •um of £50.000 toward• lh• ongolng work of Th• ELEVEX Sult Ipr•vlously known •$ The Smart Sult and Th• Arm As•l8t Sulti. When a person losos thalr upwr Y lunction ba8K tssks like bwshin9 thglr 199th, feeding Ihemselves. or huggSng 18mlly become Imposslblè. Physical barriers and 80dal barri¥r8 la86umpbons about th8ir mle and valu& In society) restrict freedom. Eventually, the barrlèrs bocom& In$unTyn13bl8. removing the ability to liv& Indendnyy. continue in education, Ure 8 job, or sustain a social lrfo. A third of pupils aged 11-15 ilh a kjrtrlemi Illn8s8. disabllity or m8di¢al ¢ondilion {d Ihglr dl88bility negatively impacted iheir ability to participate in oducalion. Ultlmatély. th're removed from public Iwe WKI b6com8 In¥A810. 80 too do their voice and needs. Th1$ mu$l change. The ELEVEX Suit wll give back what Du¢hgnn& $le8ls frorn young people by r6Storing thè usg ol their arms. the $vit will Iransfom dis8bled kids into independenl teenagers living ilh dignity. It wll transfom their lives by u.matelY delivering a measurablo Impacl on inclusion, oducalional at(ainFnenl. and participation in socsety 8t 18TrJe. We are collabofaling with Duchenne UK on thls project, whlch Is d&sned nol just to benefit the UK, but w)rfdwidg. a8 11 as olher disease areas and conililions wilh loss of upper body function. A dynamic and ¢0118borative team are Ijng on thi8 proj1. compriwng engineers, bmeChanICS 9XPgrt8. and control system speclalists. Cruclalfy. youn9 people fvom the Duchenne and SMA communibes havtr ined the den team and have actively shaped the latest concept dèveloprnonl Mx)rk, building on leamiThJ from p0S prototypes. Wg are oxtrgmely gr8tefvl lo our nderfvl supporters and to Tho 8rothwB Trust for their contribution towanl8 this project. GIn £83,000 t¢)ward• the 'H•lp th• H•art' Cardlac Grant C•ll. Our heart muscles n&ed dystrophy to function efficientjy. In Duch8nn&. a lack of dystrophin means ihat h88rt mijscles weaken ovef time. Heart cèlls arg replaced by scar and fatty tissue. vthich reads lo a type of heart muscle dis68se c8lled dilated cardiomyopathy. The age vthen thls happ$ in Dwknnne c8n vary from person to pe(s. from oafly childhood to adulthood. Children th Duchenné dony usually have cardiac symptoms. Howèvgr. weakening heart muscles are part of the natural progression of the diseasa. Therefore. e8rfy monitorirvJ. preventalive treabnenl, arml ongoirKJ management ar& important for k88pin9 th8 heart heallhy into adulthood. It is currently not possble lo prevent heart wèaknw in Duchenne complètaly. However, s16roids and heart medication can slow down th8 dodine in heart fvnction. This grant call will help us undèrstand how the heart is affected and identify rKJtentlal innovative Irealment strategias and approach8s. In response to a huge Ltnmet need in caft1c man89ement and effective therapeubc options targeted to at thè heart, leading to poor outcomes in people liviTrJ ¥th Duchenne, this will area of fiKus for vs in 2024 and 2025 and thrilled to share that Nyo eaidiac projects 8re n¢)w pushiThJ foThyard. One in rèpuryK)$ing Empagliflozin for DMD and the other an inlem8lion81 survey on clinical psentIOn and sgMeA prow6b to infomi oThJoiThJ carn.
ALEX'S WISH TRUSTEES. REPORT FOR THE YEAR ENDED 30 JUNE 2024 In addition lo these projects, we have several other active projects that wè hav$ previously supported pushing forw8T(I this year. As well as pledged support lo various projects in Ihe latter haff of 2024 and 2025. W• hav• contlnu•d to raise awareness about Duchenne Mu•eular otrOphY. Through re9ular posting 8cross our social media platfomis. about stwies, progress. medical news, ways in vthich our supporter make an impa¢l and how they can support us on the luture and are seeing an ever increasing followng and engagement online. Thank you to everyone follovts our ioum8y. ThroLYJh our calendar of events. have raising the profile of our caus& and gngaging 1th estIl¥j and new supportws. We ha a pipellne of fvndralslng support and 4ctlvlUos OT the next 12 months. In addition to the funds receiv8d during this financial year, have seen 9al $u¢¢ess th Our fundraising advltigs In the 18tter part of2024 and into 2025. W8 have se¢ured furKling from vaiious twsts and fndationS. indw1iNJ Th8 Brothers Tnjst. Delivered a caK8ndai of SLtccassful and prtsfitsblts ftJndrai8iThJ acti1186 and e¥ts lor our supporters to gel involvgd th, 80 th81 we can continue to raise rnoney to furth8r our mis8x)n. We hav& s8cur8d htndin9 from local hKJhyDfile events. 8wh a8 The Noltin9ham Hol proty Shvw. We have been I1.ng ¥trlth NE C lo devdop AX,$ Wish inspirtd Children's pyiamas to ra1 mongy for our cau88. Plus, much mw. you can find out more by followsng us acro¥s our sothl media platfonns and on our b$te. R•¢•nt •¢tlvltl¥ and achl•v•m•nts Over the ye8rs. have funded a variety of projects across a bro8d-specinJm from eady.slage r6sèar¢h through lo clinical als. funded five Clinical post5 to support clinical tn'al dov8lopm8nl and palient access, fvnded DMD Care projects, as well as invested in now l8chnologle8. He are some examples of the woth havg funded over racent yws. D•v?loplng nutdtlonal guld•lln•s, r•8oureo #nd o ¥tru¢fvr•d nutTIUonal progrnmm• Obesity is a serious health complicats'on in Duchenne. vith negative implications on cardiac arK1 rtrspiralory function. mgnl81 health. and quality of life. Num8rous la¢tors Contribute to weight gain. indudlng limited physical 8¢livity and tha u$8 of k)n9-temi steroids. Whilst the need for better diet and nutntional managemenl in tM)ys Ouch&nne Is recognised. this aspect ol cara Is not addf8ssed in the NHS, due lo lack of resources and spg¢ific guTrdance. The solU.0n 18 to develop Ihe èvidence required to affect change in Duchgnna weighl managernent care and a raThJe of rosour¢e$, tsilored to the needs of boys with Duchenne and their families, that thèy can accoss parts'cularty after initiation of steroid treatment. There Is currentty no $tw¢lured nutritional and Ight manag8m6nt guidancè availablo to boys wth Duchenne in tr+e UK. A UK wide survey of larnilies of boys showed Ihal lor 46% 01 pauents. nutritional issues are not monitod or addressed in the ¢lini¢. The survey also highlighted that Duchennè specific nutritional and lrfestyle advice is condra &ssenli81 by these families. The 2016 inlgrnation81 stsndards ol care recommerM1 that a regislett dielician should assess nutritional stslus and create a specific nutrillonal plan, both ol vknich are currently not available to UK patients throwJh the NHS. Taken togelhor. th8S8 highlight a major gap in UK carg ol boys th Duchenne. vthich we are unwuely placod to help 8ddre8S through DMD C8ffj UK and fundiA9 this project. This projecl is ongoiThJ, arKI dini¢al wommend8bons are expected In 2025. OMD Care UK project manayr pt at Unlv•rnity ot N•W$t1• - DMO Care UK has now succassfvlly opened working group5 across all agreed standards of care now 13 in totsl. Each b%Thking gfOUP is wOlg towards having published guidelines, endorsed by the relevant prOfeSonal bodi&s- cardia¢, re4M'ratory. bone and endocrine. Patient and f8mily guides have bèan pr(Xluo in p8rJllel wth a puIcation of each dlnul guideli 8nd cMsuliabon wth the Famlly Focus Group of 00 Care UK. This enabl88 patients and families lo better advocat8 for thgir Care 8rKJ to knng latest infomiation to the attèntion of their cllnlcal teams as well as to maks inft)rmed choices aboth their care. DMD Hub Is a fiagshlp project that has successfully expand•d eapaelty for clinirAI trlals for Duchenn• tr•atment8 In the UK. In the first foul years of the project, Duchenne UK. and its parther charities (including JeS Wish) Investèd £2.7rn in the DMD Hub, an additional £1.6m commrtied over the next 4 years. The DMD Hub is a collaboration betwèen Duchenne UK, the John WaKon Muscular Dystrophy Researth Centre IJWMDRCI in Newcastle, an<1 Great Ormond Street Hospi181 London. 11 was set up to expand clinical trial caparAty and Èxp8rtis8 and stop dinical trials beirKJ tumed away frorn the UK. The project tgam devgloKd the Clinical Trial Firth to help patients tnfomalion DMD clinical trials in tha UK.
ALEX'S WISH TRUSTEES. REPORT FOR THE YEAR ENDED 30 JUNE 2024 We are pleased lo share that sincè 2016. Ihè DMD Hub has.. Engaged witr 16+ companiès and 5 Clinical Research OanISatt0nS Recruited 793 boys on DMD trials Facilitated 57 clinical trials, 28 are cuffenty active, 7 at feasibilty slag8 and 4 in eaty discussions PTovided 34 posts to tscilil8t8 the day lo day and $81 up of new trials - 72% of these posts have been suslaingd Leveraged £1.3M of fundirrfJ from other fundgfs and industy to support DMD clinical Search Antlflbrotlc 8¢reenlng platfonn. Unlversity of New$110 a neAf molecular b¢ology technlque ¥thich en8bl8s us lo look inside muscle cells lor Duchenne patients. This wll help us to undersland which Ireatrn8nls are most 8ffgCtive in preventing fibrosls, a process which happens vknen muscle cells die and ar8 roplaced by fatty bssue. Fibrosis can lead to failure of th& heart and respiratory muscles, which is the most comm cause of dèalh in adutis with Duchenne. While gene therapies could be Ir8nsformalivè fof living ffith DLthenne, the progressive nature ol ihe disease limlts Iheir impact. Combining gene th&raptèS wth drugs that could reduce mLtsde deterioration. such as anti-fibrotics could help lo maximis8 the effect of these treatments. Anti-fibrokncs could al80 b8 used lo treat patienls who are not elwJiblg for gène thèrèpy, and for tho$8 in the 18ler stages of the disease. We lunded a Pho post vtho Wds suc¢esslulty appointed in August 2022 and substanbal progress has been made. yoG•n• Blo- a company developirvJ cutting edge thorapies for muscle dia$e$. MyoG8nè hB$ furthèr adv8nce¢J prgclinical development ol a gene edrting therdpy for Dvchenne a mut8tion in 4&55. The eXp"M9nts in dystrophi¢ ml¢& h8ve been completed and they will be moving on lo a larye animal model study. This ¢ould b6 the firsl gène èdilin9 th8rapy for Du¢h8nne reaching the cllnlc and are &xcllgd to see nexi stw. Llpld Nanopartlcl?• ILNPsl t•chnolo9y u$•d In COV1tr19 vaccln• to wh•th•r It could b• used to h•lp In g•n• therapy treatments for Duch•nn• - L•ld•n Unl¥•r•lty M•dlcal C•ntr•. LipHls are naturnlly OCLurring small fatty molecule$ that exist within the body. and nanoparticles releTS io their 5rnall Size. LNPS arè currently bèing usèd as a key ¢ompon8nl in tho PfizerlBloNT8¢h and Modgma COVII>19 vawne. Several clinical trials of gene therapy are now underway in Denne using hamiless virus&$, callgd A4Vs. lo deliver synlhets'c gene to replace the faulty dystrophin gene in Du¢henne. The earfy data looks pmmising. But thèrè ar8 some challenges in getting this tre8lmenl lo the 8nb.re Duchenne population, mainty because some patients wsll have prallexisting antibodles to Iha virug and so will not currèntly be able to havo the treatment. There are also difficulknes in transferring the genes trom the rUSe$ Into muscle cells. This study aimed to adsS some ol Ihese challenggs by explonng LNP$ as a method of delivering g8n8 therapy. The findings were in¢onclusive'. howpver. tho resear¢h tsam are ¢onts"nuMw thali investigallons for polenlial fvlure SU¢C8S8 in Iatment Duch¢nng. A plon••rlng Plurtpot•nt St•m Cell Th•rapy'Alt¢rtng th• nw•¢l• •nvlronm•nt to Influ•nc• st•m c•ll b•hAvlourf •t Th• UnlveTil¢y of MlnnMota 1$ looklng at re9ènarallThJ muscle in Duchenne patienis wth stem cells. Stem cells are a potenlially exciting approach to gener81tr new heallhy muscle in patjents th Duchènne. Tho stem c&lls M are looking at arg called human inducgd pluripotent stem cells liPSCsl. These cdls replace the diseased muscle tissue wlh stem cells that can creale hoalthy myofibors which are able to regenerale. The aim of ihis project is to pro(luce 8nd tes¢ these stem cells lo gel the preclinical data required to progress lo a din1 lrial. This pro11 has prov811 hKJhly successlul, this study involves ph888 1 human clinical trial testing th& safety and tolerability of slgm ¢8lls which have proven to contn'bute to $koletsl mu8¢19 rggengralion in dystrophic mice. A clinical trial recruiimenl is expected in 2025. FOR DMD PhD Pmt - Dr. Mleh•la Gugll•rl. UnIr•Ity of N•wca8tl• - the funding prowded allowed for the analysls of the FOR DMD trial, %thich 8 doub, blin<J, conlrolle(I study d&swJned to awss the latiVe effecliveness and adversa èvènt profiles in Dvchenne of Ihg 3 most fraqntlY wgsuib8d corbcosteroid wimes Idaity prednisone, daily deflazacort and Int8miltt8nt 10 days on 10 days offj. The wcyect led to 4 publicalh)ns in hvJh impact scientific joum81$ and the key outcomes were: Initiating steroids before age 6 Impmves molor traleclodes over 18 months. supporting treatment no later than age 6. Dally steroid regimes benefit ambulant Isbll walking) boys over 6 years old - enhancing motor rtOanc8. Older boys often start intermittent regimes to limit Side effects like weighl gain, but daily dosing may better mainlain motor lunCOn. Boys slarb'ng 51eroids ave motor ¢ut-off values show sustained improvement after 18 monlhs, helping predSct fvlure mtof p8rfomanca. W• •upport•d th• IGNITE DMD ISGT4011 G•n• Therapy programme wlth Solld Blosclences - we were told gene therapy would not happen in tsur liletsmès. But we did not accept that. We a pleased to say this gene therapy programme has been tested in cllnic in the US. Gene Iherapy offers hope as 8 Potentyal trealmenl for Duthtrnne. We 8r8 8Xtrgmely proud to have played a part in helping to accelerate the devehjpment ofgene therapy.
ALEX'S WISH TRUSTEES, REPORT FOR THE YEAR ENDED 30 JUNE 2024 Objectivès and adlvltiès Charitablè Objectlvès and Actlvlt 1. Th• prlnclpal oblects of the charltable company are the rellef of sickness and thg prg$•rvation of go¢xl health by supportlng sclentlfic research Into the Improved diagnosis. prevention, or ¢reatment of Duchenne Muscular Dystrophy al Extènding the current scope of dwgs l treatrnents so th8t they will help 811 children with Du¢henne MY18r Dystrophy. bl Fund first stage clinical trials that providg th& safety and efficacy of some of th8se treatments and then progress this into larger sc8le production. cl Fund th6 complèlon of scientific w)rk already begun. to bring il to dinical lrials. and (urhy other fonns of treatment that will work on all children wardless of their genetic mUtstic. dl Fund studies that will bring about dats 8nd inforrnation to help iJe¢igon makers make dacisions on lch tr8atments to bring lo market. el Fund tho DMD Cai¢ progfamme emFW)wering pati&ntslfamilies to access the best care wherever they live in the UK. Q Fund now te¢hnolc¥Jical advances to h8lp children and young adults liwng Duchenne live a better quality of life. 2. Advanee tho Odueatlon of th• g•n•ral publlc In all ar•as r•latlng to Ouchenn• Muocular Dy8trophy by dSs8omlnatlng Informatlon on thè dlua8• and Its tr•atm•nt8 and cur•8. To.. al DIss8mlnBt8 Infomation usn9 online offline materials. Inc1J1j ihe Al8¥'8 Wish Website and via our monthly ethnewsletters to our supporters. bl Running events and fundraising aclmties. including our Spring L8utKh and Autumn Lunch which sees our team, tnjstees, reprosenl8lives from Duchenne UK. and our supportèrs coma togelher lor us to share our impact during the last 12 months and Ouf plans. ¢1 Piomotlng our 5%¥) across a variety of swal media F4attornis, includirrfJ Facebook. You Tubtt. Linkèd in, Inst8gram and Tlk Tok. dl We have buitt great rèlèlionships %%ilh Ihe Icul mei1ia outws In rgglon indudiThJ ITV Caniral and BBC East Midlands and ularfy gengrale nèws articlès and updales in local newspap8rn. including The Leicester Mercury, The Loughborough Ech and local magazinès posted through doors. We appear regulady on the local radio slalions including BBC Radio Leicester lo raise awareness about Duchenne and the irnp8cI this has on f8milie$ living With it. el Talking and psentIng 81 various everbts on Cowrale sw.al Ra$pon&bility. the Impact of Ilving th Duchenne Muscular Dystrophy and About Algx's Wish -11 is Important tyjr personal story is shared amongsl othern io be the voice lor other familie 8ffgcted by Duchanne. fj Particlpat8 In alliances and liaise wlh the Govemment to infomi policy makers aN1 olh&r 8tskeholder8 about the of ¢he charity, the nature of the dlsease ènd potential trealmen18 an(1 cur9& Our Grantmaklng Pollcy and Collaboratlon The Charity has established its granl making policy to achieve tts obJectivo8 for Ihe public neffl to find a curè for Duchenne Muscular Dystrophy and to slow down the rale ol pir¥Jffjssion by maintainin9 musde strengih for loThJer leading to increas6 life expectancy 85 well 88 8 bett&r quality ol life. We only want to fund great science - projects that can Improve Ihtr knovAed9& base and brtrwj trgalmenls that can rgach the clinsc and irnprove the lives ol boys %wth DLKh&nn8 Muscular Dystrophy in many ways. We want to fund new lechnologies that wlll go on lo help those affled by OUChne. by maklng Ihe rtd accesstbl8 lo them. We fornied a parinership wth Duchenne UK. Duchenne UK share the samo mission and objectivès as Alèx'$ Wish and aro also a parenl-led chanty. As a Charity P8rtner lo Duchenne UK, r8e8iVa FWOi8Cts that qUIre co-fvndlng. All such prolect$ hav8 been r8vi8wÈd 8xlensivèly by thèir Scientific Adwsory Board ISABI bthich is made up of Some of the worfd s leading experts in Duchenne Muscular Dystrophy. They briThJ wth them a we raThJe of essential skills and kno¥edge basis including scientific, clinical and drug discovery and development. Whèn sciènb.sts approach Duchenna UK hth thèir idaas for nèw research projects it is the SAB appty ththr 8yrienc& and experb.se to test these hleas, helping to refine them, if necessary, in ordaf that Duchènne UK can make infomied deusions on ftjnding. Alex's Wish Trusloes review all projects pul fOard before decidlThJ upon specific proiecls lo lund. Dr. Alessandr8 G8ets, Ditsetor of Rèséarch and Dlopment at Duchenne UK says .1 feel very proud of ¥that we have achièved, wth Alex's Wish invaluable support. We are committed io identify and hjnd the best projects that can Iransforn DMD treatment and caTe, lo achieve better outcomes all people li¥?ng %bilh Denn0'. W& ragulady sond updat&s on prq'ect perfomiance and outcomes io our supporters through a monthly e-newsletter as well as publish updates on our swal media channels, news artides on our bSite an(1 submit press releases to the I1 media cornpanies. We have appeared on BBC East Midlands Tod8y and ITV Central.
ALEX'S WISH TRUSTEES. REPORT FOR THE YEAR ENDED 30 JUNE 2024 Achl8vement and perfomianeè Our Malor Achlevements - Co-funded 36 projects across a broad-spectrum from earfy-sfage research through lo clinical trials, fvnded 5 elinic81 posts to support clinical trial development and patient accèss, funding OMD Care proiects, as WEII as invested in new le¢hntslogi8s. Here are just a few examples of Ihe work have lunded lo de. - The Smart Subt reyolutlonary t•ehnalo9y for upper body str•ngth and functlon in children living Du¢hènne. Thi8 Surt funded by players of PpIe,$ Postcode Lottery, (chen9 UK. Wex's Wish and Joining Jack - helps dls8bled pgople keep the use of Iheir aims. Thè project officially stsrt in July 2022. and since then the projecl has developed al 8 fast pace. Followng the research carried out young people. families. and clini¢ian$ 81 the end of 2023. three new concept sionS have been created. and rk coniinues to pfogress in 2024. We wll conts'nue to support thi$ ongoing ¥Tk. Th• DREAM WhMlchalr - transfomiirKJ th& livès ol young whg8kth8Fr users. In 2017. in partneTship th Wh122-Kldz. Ouch8nne UK won a £1 million grant to devebop a new whèelthair which is al the w)rkiryJ prototype stage. Thi$ proje¢t will explore all the options on how can bring the chair to ma61, %•thich wll ults'matety irnpfov8 Quality of life for wheelchair users. Alex's Wish gave £40K to the project. a further £20K provided by St. Jame$'s Place Ch8ritable Foundation and an addltional £5K by Th¢ Brothers Trust. For children and youThJ people living wth tchanne, using a whoelch8ir Makes all the dlfference to th¢if Ind•ndeNC&. But. dgsplte huge advance5 in technology in almost every area of lif8, design and functionality of wheelchairs has changed litue in 15 yèars. Getliw up a kerb, seeing vthal is behind you, èven h8n9 somewhere to PLrt your phone- things the fesl of us barely nob"¢& in our lives- a major tasks for young wheelchair users. The DREAM Wheelchair prole¢l Is dtrsvJned to bring vkneelchairs inio the 21sl century. transfomilrwj young INes. G?ne edltlng Iheropy to acc•lerat• th• In•t19allOn• Th••d to tran$lat• 8t•m ¢•ll-b•tsd approach•s or g•n• th•rapl•$ Into cllnlc•l trll• or appllcatlon In PaonI*. Th8 bjnding lor ihis Pfoiect wll support testin9 8 gene-editing therapy for Ouchenne in preclinical models. This study is makiThJ gmat prrMJrÈss against all aims. Sm811 and large animal sludlès 8r8 now und8May. - DMO Hub Manag•T 18 a flagship project Ihat has successlully expanded capacity lor clintcal trials for Duchenne treatments in the UK. In the firsl four years of the projecl. Ouch•nn& UK, and its patln8r ¢harilig$ lindudtrwJ Alex's Wish) Invested £2.7m in the DMD Hub, with an 8ddition81 £1.6m commilted over the next 4 years. The DMD Hub is a collaboration betsveen Duchenne UK, thg John Wallon Muscular Wrophy Rese8rch Cenlre IJWMDRCI in Newcastle, and Gr6at Ormond stet Hospital London. 11 was sel up lo expand clinical Irlal capacity and 9x'S$ and stop clinic81 in'8ls being tumed away from thg UK. Tha project ieam developed the Clinical Trial Finder lo help patiènts a¢¢es$ infom8tion on DMD clinical trials in th6 UK. Thanks lo the DMO Hub, lo dale, more than 574 boys have been recnJited sinco It was e$tablishod in 2016 to clinical tr1815 who oth6rwlso may not havè bèen. Emma Heslop is the DMD Hub Manager and is key to the success of this project. Working closely wth Ihe Duchenne UK t8am, she 8nsurgs p81ienls are appropriately reSented as key slakeholdefs in all aspocts of the DMD Hub. As part ol ihe leam at the JWMDRC In Newcastle. she ha$ diréct access to ¢lini¢ians and industry partners throLtgh the relationships she has csjltivaled over the years. As Ihe main poinl of conia¢l for all ¢ompani¥s with 1ri8ls coming to the UK, she 180 promot0$ thg UK 9$ an 8ttracbve place lo wun DMD trials and vrkS them lo support s4ta s&l8cllon, set UP 8nd pab'enl recruitmènt. Antlflbrotle 8er••nlng platform (8 new mole¢ular 01(JY technique lch enables us to look inside muscle cell8 lor Duchenna patiants. This will help us lo uAd8rstsnd vthith trealments are mosl effective in preventsng fibrosis, 8 process which happens when muscl6 cells die and 8fe replaced by fatty ti&sue. Fibross can Sead to failure of the haart and SpiratOry muscles, which is the most common caus8 of death in adutts th Du¢h&nne. While gene therapies could b& transfom181ivg for Pgople living wth Duchenne, the prcoressive natu of the disease limits th&if impact. Combining gèntr therapies wth drugs Ihat could Tgdu¢& MU1$ deterioration, such as anti-fibrotics could help to maximise the effect of these treatments. Anli.fibrotics could asso be used to treat pati8nts arè not eligible lor gene IherJpy. and for those in the lalar stag9$ 01 th& disease. We funded a PhD post ¥¥ho was successfulty apwnted in Au9usI 2022 anil $ubstantral progress has bèèn m8de during Ihts first yèar, the interim report showed thal Ihe first aim of characterisiThJ the potential cytotoxic effecl of the selected drugs in hos bgèn ¢ompl$led and treatment proved safe to pycgress to in vivo studies in mouse mod&l$.
ALEX'S WESH TRUSTEES, REPORT FOR THE YEAR ENDED 30 JUNE 2024 Upld Nanoparti¢les ILNPSI tèchnology used In Cov119 vacdn¢ to seè whethèr It could be used to help In gene therapy trgatments for Duchénne. Lipids are naturally occurring small fatty molecules that exist within the body, and nanoparticles refers to their $m311 Size. LNPS a currenuy being use(1 as a key ¢omr>onent in the Pfizerl8ioNTech and Modem8 COVID-19 vaccinè. Several clinical trials of gene therapy are now undèrway in Duchenne using hamless viruses, called AAVS, to deliver synthetic gene to replace the tsulty dystrophin genè in Duchenne. The earfy data looks promising. Bul there are some challenges in gelting this trealmenl to the enbrè Duchenne population. mainty bec8use some patients wll havè prè-existing antibodies to the virus and so will not culnVy be abse lo have the treatment. There are 8150 difficulb'gs in transferring the genes from the virusès into muscle cells. This study aims to 8ddr8$5 some of these challenges by exploring LNPS as a method of delivering genè tt)erapy. The study is called 'mRNA Targeted Therapeutics for Duchenne Muscular Dy8lrophy' and 11 be led by Professor Shenhav Cohen al Technion Instsiule of Technology. Israel, in partnership wlh Prtsfessor Aartsma-Rus at Leiden University Medical C&ntÈr and Professor Peer at Tel Aviv University. LNPS can b8 filled wlh a variety of materials. inclu(ling genetiG mat&rial. Because LNPS are made of n8lurdlty occvrwing lipids. they should not causa an immune response. They also have a good safety Profile for use in humans. Thi$ study will explor6 %%kn&ther a larger dystrophin ¢onstruct can be carried by Ihe LNPS. The dystrophin gÈn6 is thè largest gene in the body, but in current g8n8 therapy trials, a shortened construcl musl be useil. Our cuwr8nl UndetandIng of the impacl of Shortened dystrophin on long-tami muscle fvnclion is limited. but U51ng 8 longer 9en8 could lead to better muscle function. The research group plan8 10 engineer the LNP surf8ce such Ihal the LNP will effectively fuse wth muscle and deliver sts cargo. This research is currently in very early stages. If Ihg re8&ar¢hers can show Ihal this method can effectively delivèr gèn8tic material inlo muscles using mouse model ol DMD, they would have a high char0 ol receiing a much larger grant lor fvrth8r research. The 1.year report was r8c6ived In May 2022. and highlighied the rbeed for an ¢xt&n&on, %thich granted. The project team 8uccesslully completed lh8 preparation of tho n8noparti¢lgs', IKthv8r th8y ware delayed in stsrting anim81 studles. which 18 now ndeay. - W• Inv•8ted In a plonMrln9 Plurlpot•nt St•m C•ll Th•rnpy 'Aft•n9 th• mu•cl• envlrMm•nt to Influ•nc• •t•m e•ll behavlourf at Tho Unlverslty of Mlnn•sota bthich is looking at regeneraliro rnusc in Duchenne patients wth stem cells. Stom c8lls are a potentsally ex¢rting appioach to gen&rate new heallhy rnu8cle in patstrnts Duch8nn6. Th& $1gm c8lls wa are looking at are c811ed human indLTrC8d pluripotent stem cells liPSCsl. Th&se cells replacè the diseased muscle tlssue with 818m cell8 Ihal can Cfgale healthy myofibers vthich are abltr lo regeneralg. The aim of this projecl is (o produce and test these stem co11s to gèt tha predinical data required to progress lo a dinical trial. This project has proved highly successful, and the 8ucc8ss of the findings h881od lo IND-8ubmi8wn and lh& Initiation of a Phase 1 Clinical Trial In 2024. A study that 18 pavlnq the way lor Improv•d d•t•ctSon of h•art dls•a8• In femal• cath¢r• ol Du¢h•nne wlth D• L 8orthwlck and Dr John Bourke at N•w¢utl• Unlv•rnbty- lollowng this tnveslrnent, a pl&asgd to Say that this proje¢l has improved understanding ol heart muscle disease in 18malè carriers. pawng the way lor further research. Women 8nd girl¥ who cary a mulaled Duchenne gene l¢aniersl can sometimes show mild syfflptryns ofthe disoasès. Duchènne carrièrs am at sk of develo.ng ¢8r(liomyopathy, which affecis Ihe abil¢ty of ihe he8rt lo pump blood around the body. Currently Duchenne l&m81e carrièrs 8r8 advised to have their hearts checked ev >5 or8 by iaking scans SLKh as ECG, echocardiogram. or MRI. Howewr, quicker, and more cosl-effe¢liv& ways lo d&tect heart problems would prevent late diagnosis and enable 88rfier treatment. De Borthwick and Bourke 8xamingd the heart bssue of patients and used this lo K1¥ntify molecule$ in thè blood thal could act a5 biom8rkers lindicators ol damage lo the heartl. This study has rthv coma to a close. and tho praliminary data shows Ih&so biomarkers have the potential to delecl earfy ¢ari1iomyopathy in a way Ihal is fasl. reli8ble 8not cost-effective. The biomarkefs need to be tested in cohorts of fem8b& carrigrs. as well as Ma Duchenne patients, lo be fvlly v8lid8led. This pilot project has laid vital foundations lor futufe rearch to improve the speeLI of diagnosis and Irgatment of cardiomyopathles. W• hol fund • PhD po•t at Th• John Walton Muocular trophY R•M•r¢h C•ntr• at N•wcastl• Unlv•r•lty spacifically to look at the FOR-DMD Study lffinding the opljmum Steroid regime for boys living with Du¢hgnntrl supervise(J by Dr Mlchela Guglieri. The PhD post will ensure ¢hal thè dala generated by the FOR-DMD study wll b8 usèd to addrèss nèw elinlcAI and research qyestions, and well as sharing the fesulis %%ilh the community. p0sblY through a series of webinars In 2024. - W• ar• helplng Impro th• 8ucc•s• rat• of clSnScal trlal8 IPC Sll¢oxI this prniect is OrkIJ Professor Mann and Dr Borthwick from the Newcasue Fibrosis Research Group in the University Biosciences Inststuta. Wè had some devastating news 81 Ihe gnd of 2019.. the eady terniination of a clinic81 tn'81 run by Wave Ltfe Sciences. The news was a big blow. not least b8causè 88rfy daia in animals had shown that the dru9 was effectively produung dystrophin. How could a trial that Showed such h promise in animal models not deliver results in humans? Earfy-stage tests are done on mie8 wth Duchènnè and thèn translerred lo trials in peopla - but thèrè is uncertainty vthether a drug rnh1 behavè thè same in the human body. We want to slop this. Thavs why we supported Ihis projecl. vknich has the tx)t9nlial to help us unders(and, al a much earfier stage of rèsearch, whether a medicine will help treat Duchennè patsenis. The project has been hil by a redu¢lion elective surgeries and heart transplants due to COVID. but somè malenal and anal$ was still able to tske place during this timè. A 12-month no cost extension was granted, to able the Pho studenl to cornplete their studiès, and interim POr1 was received in June 2022 which showed YO1 progress. and Ihe proj'ect has demorbstratod the tranational advanlages 8nd benefits of interrogating dlsease mechanisms. identifyiry new th*rap8utic targets and lestirrfJ novel compounds in th8 more tran£tIOnallY relevant human Precision Cut Slice platfom.
ALEX'S WISH TRUSTEES. REPORT FOR THE YEAR ENDED 30 JUNE 2024 We supported the IGNITE DMD ISGT-001) Gen• Therapy programme wlth Solld B50s¢len¢¢$ we were told gen& thtrrapy would not happen in our lilelimes. But we did not acwl that. We are pleased to say this gene therapy programrne has been tested in clinic in the US. Gene therapy offers hope as a potenlial trealment for Duchenne. We are extremely proud to have played a part in helpiry 10 8wlafate Ihe dèvelopment of gene therapy. In Sepiernber 2022, Solid 8nnouno8d that it had made a stral8gic decision to priorilise sGT3. their next%eneratbon AAV gene therapy candidate over SGT4)01 it's firsl%gneration geno therapy Candale. News in January 2024 announc it has been granted orphan drug designation from the FDA for SGT-003 which now frjrthers their efforts to meet the ongoing challenge of treatitvJ this devaststing disease as expeditiouY as pos%ble, these desgnations ar8 important milestones. supporb'ng the conb'nugd development of next-generation therapi88 for Duch¥nng. Solid is now currently in the process of securing approvals from th8 inslilutional review boards IIRBI al th8 clinical lrial leS for the ptanned Phase 112 clin1 trial of SGT4)03 and expects to Commence pabent scr88ning shortly thèreafter. Patient (Sostng in ihe trial is expected to comménce in mid-to-lale first quarter of 2024. - Wo •upport•d a Sy•ar p•rlod1201&20201 L•cturn8hSp Po•t (Dr Mith•l¥ Gugll•rl) - and w8 ara delighted to report the outcom8s of this grant, which was supported by a consortium of seven UK ch8rits9s, Alex'$ Wish joinèd by Duchenne UK. Action Duchenne, Duchènne Rèsearch Fund, Duchenne Now. Duchenne UK, Harrison's Fund and Joinlng Jack to invest a total of £250.000. The Clinlcal Trials Lectureship granl enabled Dr Michela Guglieri to act as th& Clinical Research Team Leader thin the John Walton Muscular Dystrophy Research Contro in N%s11e." a key role in one of the UK'S biggest Duchenne research centres. thal ensures trials ar8 run smoolhly and safely, and generate good quality dats. The project has Supported the eslabli8hmenl of a stron9 Clinical Sea(ch team at ihe John Watton MUul8r Ctystrophy Re$8ar¢h C8nlrg and of nats'onal and inlern8lion81 cgllaborations and neh¥oS lch wll play a key role in ensuriNJ th8 clinical research in Duchenne Muscular Dystrophy %thll continue to come to the UK and lo 8slablish the UK as an expert and eificienl country to deliver best Car practice and dinical research. Since Kl8y 2017, 8s well as IrainiNJ and supporting Ihe slaff in the clinical research cenlre, ovèr the COUfSe of the grant, Dr Guglièri has lsd 10 clinical trials in Dvchenne. includirKJ Th& FOR DMO Study and The Vislon DMO Trial, le81ing th8 saftrty and •tteclNeness ol Vamorolone a pot8nbal dru9 that arCherS hopè could tsr some of tha effec15 of steroids with fèwer side effects. The support from the 7 different ¢hantses has nol only resulted in signlficant irnpact during tho years of funding. but also 8 permanent position fof Michela through Ne*rast18 University. In ihis role, she wll continue to work as Clinical ReseaT¢h L8ad. supportiThJ clinical Sear¢th activities as well as nattonal and inlem8lional coll8boralions lo improve care, treatmenl and research opporiunities for people liwng with Dychennè muscular dystrophy. -Irom.alexs4¥i h-hel Svfund henn h -dmd- lini Flnanclal r•vl•w Flnanclal R•vl•w Income from donali<y)$ and fund.raislng activlli85 for ihe year awKJunled lo £285.91312023'. £343.7441. Bank Interasl recaed in tho year amounted lo £1,16812023.. £8341. Expenditure incurred 18 8$ shovm on the detsilgd statom8nt of financlal activities induded.. expenditure on fvn(l-ralsing adivlts'es which 8mounled lo £49,84212023'. £512011. Overheads include payments lor 8drnini51rati seNi¢e$ and thè management of events and fundraising 8ctsvib'e8 of £79,555 12023.. £66,419) and other ¢ost8 relabng to profftiOnal materials. Trustee expenses, insurance. bank chae5, markaling. bookkeeping. and netwothlThJ 6vents of £29.11512023.' £28,033). Payments towards research and dinical trial8 8mount8d to £113.CKKJ 12023.. £288,109). Iknrall, there were ntrt incoming resou¥ces for the year of £18.94012023.' OLrtgolr¥J £89.1841. Flnanclal Reserves Pollcy Thè Charities SORP requires a charity its stste th& amount ano type ol financial SSIVeS it holds. and to compare how the level of those reserves matches up lo I61 of selVeS the trustees feel as appropriate given Ihgir plans for thtr fvlure 8ctivitlOS of the charity". Where it falls short, Ihe truslees need to explain %that steps they ar8 taking to rectify thè situation. In this cont&xt, the charily views financial reserves as those held in its ynrestricted funds. the balar of fvnds stood at £71.832 al ihe yearond12023 £52,592). The Truslees e8tsblish the appropriaie level of unreslricled reserves lover and atrKJve those already rlro-fenced lor plans or known liabilities within restricted and designated Funds) by seekirYJ to ensure that the Sevel of Ihe charity's Yree serVeS. meels a chosen benchmark related lo Ihe budgétad &xpenditu for unrestricted activities. The Trustees consiijer the 'free serves. lo be the unreslricteil funds not committed or invested in taThJible asseis. A5 8 result of a full and objective revièw of Its Y rèsèrves, policy, considering all the risks fwe5eeatAe al thal wint afid tho charitys approach to their mitigation, the Trustees agreed on 9th February 2023 that £30.0 should m8intain&d as Yree serveS.. This level has continued to be reviewed for adequacy and robustness to ensure thè Charrty maintains adequale finarbces to meet day-t¢daY opèrating Gogts, and we wll ontinue lo rewew this over the comirKJ months. As of 30 June 2024, the Charitys 'f reserves. stood at £71,832 12023: £52,892), r6suMng in a s¢Jrplus of £41.83212023'. $urplu$ of £22,892) vthen cornpa with the current benchmark, calculated as £30,000. 10
ALEX'S WISH TRUSTEES. REPORT FOR THE YEAR ENDED 30 JUNE 2024 Strateglc approach and plans to fulfbl our charltable objectives In the corning year we plan to.. Obl•ctlv• 1.. To IdentSfy, fund and monitor mlea1 f•s•arch projects, cllnlcal trlals. cllnlcal trfal capaclty opportunltl•¥ and new t•chnologlcal advanu$. To receive updates on outcomes for proje¢ts lunded so can pOrt on the impact those projects have made to help progress our mission. To repc>rt on Ihese via our news feeds on our ble. our soci81 media platlom$, è-nawslettèrs lo our supporters. through local p$S coverage and al our events. Continue to work closely wth Duchenne UK 8s a Chaiity Pathwr. To seek out and fvnd new projects that fit wth our mission lo conquer Duchenne - lo improv8 and extend Ihe lives of everyone affected. Ensuring that our fvnds afe spent effectively and In th8 right areas to help bring atKJul the best chances of bringing new Ireatsnenls to market. Incrèase our level of income generated each ye8r by buil¢Jing tiOnShIpS with our es11j supporters as well as ailracting now wpporters lo cNJr cause. Continue lo lund pro19$ that wll brirvJ at)ut effective treatments. technolc4Ji8s. improve care stan(Jartls. and Improva cllnScal trial capac¢ty in the UK for the LMKhenne ¢ommunrty and 8im to give £150.OOO+ per annum. Obl•ctlv• 2.. To •ngag• wlth m•dla and our upport•rs to •rn•I of Ou¢h•nn• MuBcular Dy8trophy. Attend thè annual Horizons Conlerences held by Duchenne UK lo engage with otr paronls affected by Duchenne Muscular Dystrophy, as I11 as keep abreast ol laie81 prcJre5s made in the figld of Duchenne. To be actively involved in workshops and meetings alongside Duchenne UK that is l(xussei1 on improving care stsndards in ihe UK. Whera p08slbl&, attend national gvents and meetings to help lobby MPS ènd P8rfbam8nl lo brlng about now IalMents to markg108 quickly os possi8 e.g. VamorrAon8 and Givirtht81. Issue press r8108ses ar)d submit lo ¢h& local press in the East Midlands to help raise awareness about tho we 8re dolng and 118 impact on the lo¢al ¢ommunity I the rost 01 th8 UK and to help attracl new supporl8rs lo ouf causa. Continue to S8nd monthly updates lo our supporters è-ngvA8tt8rs. add newS%rthY contenl lo our webslte and regularty pos( and grow our supportgr base gcross our 80cial medsa pL8tloms. Org8nise Supportgr gvents InclLtdlng our annual Spring Launch ènd our Autumn Lutrh to kegp In touch Ouf WPPOrt6rs 8nd guests about the vltal thal do. and howlhgy Cgn ¢ontmue to help us. Continue lo attend netrrkIng ev•nls wthin the regn to build new and foster 0$119 reklionships and attract nw support&r$ to our ¢au$g and arrarge 121's wth business supporteTr on how Can collabornlo and foster folationships. Continue to speak at Communlty and bu$ine$$ &vents there opporbjnities to ari8e. Obl•ctlv• 3: Incom• G•n¢ratJon through our flag•hlp •v•nts. 8upport•r OAt* and lundralslng a¢tlvltl•i. Organise and build on our fl8g$hip •v8nts'. Annual Charity Gotl Day, our Supercars event, Charity Foolb811 Toumarnenl, Charity Grdnd Prix event. Fashion Show collaborating wAth other IcKal charities. our Annu81 Fundrai$in9 8311 and The Big Christm88 Givè campaKJn. Our focus is on coveriryJ costs, makiNJ an iMt Vth the amount of funds ralsed, and provlding a fun and enloyable fundraisng experience for OUT SUPPQrters. Support olh•r organigations, gmups and individuals decNJe(I lo org8ni8e thelr events In support of our Us¢. providlng resources and (tme to support them achitrve their funt1raisiThJ goals. To attract supporters to tsko part in the LoThlon Marnthcffl. ¥Ydlkiro and runniThJ events. chall¥nge events e.g.. zipwrg Challèngès, skydiwing, loop the loop aerO.C displays, wirwJ walks, and absèil ¢hall&ng8s and to raise as much monèy as Ihey can doitvj so, by providing ihem wlh the tools arTrd encouraggmnt to do so. Retain our $xisting regular giving supporters and develop new iniliatives to grthv our r8gul8r giwng wpporter b889, through our '8è More Alex. £7 a month regular giving campaign, our BUn&$S Community £75 a month wular subscription in exchange for business benefi(s such as organising local nel4wln9 events to bring the local business community together. Conti¢iue to support busrn6sses donate a percen18 of their inC(X to us mry &ThJle month and Iix)k to attract Ilke-minded business. We 8im lo wthin 8 30..70 ralio of cost vs. irm received from an event to ensurp th8170% of what raise from our èvents oveiall goes directly to fund projects to further our mission. Wè like tr) attract more capital through corporale sponsors to cover mosvif not all our event sts to help improve this ratio fvrther. We have been successful in attracling corporate sponsors and wll continue to build on those relationships.
ALEX'S WISH TRUSTEES. REPORT FOR THE YEAR ENDEO 30 JUNE 2024 Majority of our income rdised has been through Iw)stirwJ our ly0 events. aim is lo ntinue %bx)rkn'ng with local businesses to lak$ Alex's Wish on as their chosen chanty and or9anise their ovm events and consider Alex's Wish as th8ir Charity of the Year. This means that of the money they give to us as a Chartty goes directty to lund projects lo lurthèr our mission as they do not incur the expenditure that our own fvndratsirwJ 8cliwbes require. Contsnue lo Vrk wilh charitsble found8tions %tho have kindty supported our work, as 11 as other kK81 charitable groups, to sour¢e additional income. We are now Out1¢Ang this important Y)rk to an expert in this field tr) help us id&ntify and 8ppro8ch ngw trusts and foundation opportunilies. We have seen success in this fiekd. and hop& to continue to find morg success as we diversify our incorne sireams. Form strategic 811ian¢es and partngrships wth oryanisatims sh as local SKK)rting clubs. ¢0118g&s. h0o18, and Corporatè businessès. We hop8 in the ftjture to launch a podcast to furiher our reath and atiract audnCeS to our cause. Structure, governanc• and mana9frm•nt Govèrnlng documont The charity is controlled by its goveming document. a deed of trust, and constitutes a limited company, limited by guarant98, 88 defined by the Companies Act 2006. Tru8t•• R•crultm•nt Trustèes wll be recruited through recommendations and social m8dia, al our events and through word of mouth. Those expressing an interest wll. in Ihe fIt instance. b8 met by Ihe Charity Founder. given an oveNiew of Ihe organi$8tlon, and encouraged lo apply. The Chair and Co-chair trustees will examin8 the applicab'ons against the most recent skills audit, oduee 8 short list. and invite those ort il lo submit their reloren¢tr$ and then attend an interview.. the Chair and Co.Chair wl conduct the inlgfyiows, and make re¢omm6ndations to thè 8oard. Al Tts next mlIng. the Board will review thesè r8commendations, and either ratify or rejecl. Successful applicants will be asked to complete and 84gn thè Oèclar8tion of interest lom, sign a declaration ihat Ihey are eligible to serve as a trustee.. and agree to the code ol conduct. They wlll then become a Iwstee of the Board. Organl•a¢lonal •¢ructur• The organisation is a charitable company limited by guarantee. incorporaled on 22 June 2012. The company was eslabllshed under a Memor8ndum ol A550Ci8tion vthich est8blishgd Ihg objecls an(J powers of th8 Gh8ri¢able company and is govemed urbder ils Articles ol A880¢ialion. lft th$ ent of the Company boing up mombw$ 8re roquirèd to contn'bule an amount not gX¢gèdlng £10. The body responble for management of the Charity 18 the Board ol Twuso5 of Alèx's Wish. Tho 803rd meeis monthly land al least len bme$ per yearl. Tha ¢harity's ¢on$ts"lulion is sat in th& Articlès of Association, and all TnJsleo5 have agreed 10 th1$. N8w Trustees are appointed by the eStsng Boa of Trustees. Tnjstees give of their time freely and no Trus189 remunerallon was paid in Ihis year. Delails of Twslee expenses and relaied paty iransactions are disclosed in the accounts. Trustees are required to disclose all relevant inierests and to wthdraw Irom dwsions where 8 conflict ol inlerest aris8s. None of the TNsl8es have any interests wlh the phamia¢&utical Industry. We re9ularfy revlew our stated alms. objectives. and actiwbes to ensure are %thirBJ toward our stated purposes. We hav referred to the guidance contained in the Charity C¢)mmis'on'$ 9trner81 guidare on public ben8fil under the Charities Act 2011 when Setting and wiwng our aims and objectives and in plannirvJ our fvturo titiO$. All our charitable actiwb'es focus on ImprovSThJ iho1Sves of those vAth thjchenne MusrJJlai Dystrophy. Rlsk m#nag•m•nt Thè Tru5t86s conttnu8 to r8vi8W the major strat8gk. busln8ss. and op8rattonal dsks vknich th8 charlty fac88 and ¢onfirn that systems are in place lo enable regular reports to be produced so Ihal the ne$sary sleps can be taken to lessen these risks. In assessing risk, the Trustees recc*Jnise that some areas of the require the acceptsnce and management of risk rf the charity is lo achieve its objectives. Appmved by order ofthe boa of trustees on 25 March 2025 and signed on ils behalf by.. Mrs E J Hallam- Trustee 12
INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF ALEX'S WISH Indepelldgnt èx#mln•rfs report to the tru$t•es of Al•x'S Wish Companrf) I report to the charity trust&Ès on my examination of the accounts ol the Company forthe year en(led 30 June 2024. Responslbllltles and baBls of roport As the charily's trustees of the Company land also its dbredors for the purposes of company lawl you are resw)nsible fvr th$ prepar8tion of the accounts in accordance wth the requirements of the Companies Act 2(KJ6 Ilhe 2006 Act'l. Having satssfie(I mysell that ihe accounts of th$ Company are not required to be audited under Part 16 of lh& 21)06 Act and ale eligible for independent examination, I rgport in respect of my examinab.on of your charitys accounts as carried out under Section 145 of the Charities Act 2011 Ilhe 2011 Act'l. In carrying oul my examination I havg followed the Diiections given by the Charity Commission under S8ction 14515} Ibl ofthe 2011 Act. IndonOnI •xamSnerfs 8tat•m•nl Since your ch8nty's gross income &xceeded £250,OCN) your 8X8minÈr musl be a member of 8 listed body. I can confirni that I am qualifièd to undertake the gxaminalj.on because l am 8 memb&r of the Assou'ation of Chartered Certffied Accounlanl8, which Is one of the listed bodi&s. I have compl8t8(I my &xaminatKJn. I confiwrn thal no mattws have comè to my attention in ¢onrCtion swth the examination giving m8 Cou to believe.. accounting records not kept in resp8¢1 of the Company as required by Sgctlon 386 of the 2006 Act.. or the accounts do not accord wth those recorfs., or the ac¢ounts do not comply with tha accounbrMJ requir&m8nts of Section 396 of the 2006 Act other than any ouirement that the accounts givè a true and fair vw4 which is nol a matter considored as part of an independent examination., or the accovnls hav8 not been Prepar in Accordance with th8 methods and winciples of Ihe St81emenl ol Recommendèd Practice for accounting and reportiro by charities (applicable to charities preparing their a¢counts In cc¢xdanc& wth the Finarbcial R$wrtbng Slandard applicalAe in tha UK and Republic of Ir&lan(J IFRS 10211. I have no concems and have come acros5 no other matlefs In connection with the gxaminalion to vthi¢h attention should b9 drawn in this ieport in ord8r to enable a proper unt1èrstandiThJ of the accounts lo ba r&ached. J Petha FCCA Th6 A8$0Ci8tlon of Charterèd Cwlfigd Acccwjntants Sturgess Hutchinson Chartered Certified Acwjntsnts 21 New Walk Lel¢6$ter LE16TE 25 M8rch 202S 13
ALEX'S WISH STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 30 JUNE 2024 2024 Unrestricted fund 2023 Total fijnds Notes In¢om• and •ndowmgnt$ from Don8bons and legaci8S 37,644 43,447 Charftable actlvltles FLtnd-raising activities 248,269 300,297 Investment income 1,168 Total 287.081 344,578 Exptsndlturo on Charltable actlvltles Expenditurè on ¢haritsble events Administrative services Payrnents for medical research, cllnical posts aThJ new technologies Support ¢os¢s 46.471 79.555 51,201 66,419 113.1 29.115 288,109 28,033 Tot•1 268,141 433,782 NET INCOMEIIEXPENDITURE) 18.940 189.1841 R•conclllatlon of funds Totsl funds brought fomard 52,892 142,076 Total fund• carrl•d fop*ard 71.832 52,892 The noles fcm part of Ihese financial slatements 14
ALEX'S WISH BALANCE SHEEr 30 JUNE 2024 2024 Unrestrictgd fund 2023 Total funds Noles Curront a88•ts Debtors C88h at bank and in hand 16.083 68,138 12,979 54,949 84.221 67,928 Cr•dltor8 Amounts falling due wthin one year {12.3891 115,0361 N•t ¢urr•nt a8s•t8 71.832 52.892 Total a8•et¥ le•• ¢urr•nt114bllltl 71,832 52,892 NET ASSETS 71,832 52,892 Fund• Unreslricled funds 71.832 52,892 Total funds 71.832 52,892 The charltable company 18 entltw to exemption trom audit under S8Ctlon 477 of tho compani Acl 2(M)6 for the year ended 30 June 2024. The members have not required Ihg company to obtsin an audit of its financial $t8temgn for the year ended 30 June 2024 in accordance wth Secliort 476 of tho Companie8 Act 2006. Tho Iru$l8es ackno¥edge Iheir responsibilitie$ for lal ensuring that the ¢harit8bl8 ¢ompany ke8ps xcountirwJ records Ihèl compty i¢h S8Ctions 386 and 387 of the Companies Act 2006 and poparing financial statements vknich give 8 true and fair vi&w of th8 stale of affairs of the ¢harit8ble company as 81 the ènd ol each financial year and ol its sulUS or deficii for each financial year in a¢¢ord8ncè wth the requirèments of Secuons 394 and 395 and which otheTh%ise comply Vth th8 requiremtrnts of thè Companies Act 2006 relating to financial ststements, so lar as applicable lo th8 ¢haril8bte company. Ibl Th&s8 financial statements have ten prgpafgd in ydanCe wih the provisions appli¢able lo ¢harliable compan1 $ublect to the small companies regime. Thtr finan¢i81 $lat8mants V*pre approved by the Boaft1 of Tru$t8eS ond authl88d for i88uè on 25 March 2025 and signgd on its behalf by.. Mrs E J H811am- Tru8190 The notes fomi part of these financial stslem8nts 15
ALEX'S WISH NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2024 Accountlng pollcles Bas18 of preparlng the finanrial statèments The financial statements of the charitable company. is a publK benefft entity under FRS 102, have boon pr6pèred in accordance wth the Ch8rib"e$ SORP IFRS 1021 Accounb'ng and R$porb'n9 by Charibes.. St81ement of Recommended Practice 8pplicable to chanties pParij their accounts in a¢cordance wth the Financial Reporting Standard 8ppliG8ble in the UK and Republic of Ireland IFRS 1021 leffective 1 January 20191., Financial Reporting Sland8rd 102 The Financial Reporbng Stsndard applicable in the UK and Republic ol Ireland, and the Companies Act 2006. The financial statements have been prepare(l undar lhè historical cost convention. Income All incorne is rg¢(yJnisèd in the Ststemenl of Financi81 Activib"tr$ once the charity has entitlement to the funds, rt is probable that the iome will be received and Ihe amounl ¢an be measured lIablY. Expendltur• Liabilities are recognised as eXndIture as scwjn as Ihere is a legal or conslru¢tive obligation commiWn9 the charity to that 8xp8ndilvre, il is probablè that a Iransfer of economic bengfits wll requlred in settlement and the amount of the obligation can bè measured reliably. Expenditure is accountèd for on an accnjals basis and has been classified under h&adirKJs that aggregate all cost rdaled lo th& category. Whefe costs canrw)t be dirtsctly attrlbuttsd to particular h6adiThJs they have been allocale(l ¢0 activiliès on a bass consistent the u8e of $OUrCes. Taxatlon The ¢harity is exempt from CoTal tax on its ¢harbtabl& actiwtios. Fund •¢¢ountln9 Unrestricted ftjnds Can b& usfjd In accNdanr wth the ¢haritsbl8 obie¢tiv8s at th8 dlscretlon ofthe trusle8B. Hlr• purcha•• and l¢a•ln9 ¢ommltm•nts Rgnlals paid under operaling leases afe ¢hafggd to the Ststement of FInalJaI Activities M a str8KJhl I[ ty8sls over the period ol the le38e. P•nslon co8t• and oth•T PO•t-r•tlr•m•nt b•n•fits Th• charitable company operJle8 a dtrfined contnbuuon panOn scheme. Contrfbulions payable lo the ch8ritsblo company's pen&on scheme are ¢harg8d to the Slalement ol Financial Actiwt8 in thg peri¢)d to which thgy rglatg. Inv•stm•nt Incorn• 2024 2023 Deposlt account inter081 1,168 834 N•t In¢om•ll•xp•ndltur•l Nel in¢omell8xp8ndlturel Is stated after ch8rgiThy{¢r¥dititvJI'. 2024 2023 Other op&ratlThJ leases 7.140 3,570 Trust••s' r•mun•ratlon and b•nefft• There were no tru5tee5' mUnatiOft or other beneffts tor the year erHJed 30 June 2024 nor for th& ygar gndèd 30 June 2023. Trust•es' expens There were rK) Irusle¢s' exwnses paid for Ihe year ended 30 June 2024 nor for the year ended 30 June 2023. 16
ALEX'S WISH NOTES TO THE FINANCIAL STATEMENTS- continu•d FOR THE YEAR ENDED 30 JUNE 2024 Staff costs 2024 2023 Wages and Salaries Other pgn$ion costs 77,943 1.612 64,946 1,473 79,555 66,419 The aver898 monthly number of employees dLtring the year was as folbws.. 2024 2023 Administration No èmployees r8coived eMmentS in excess of£eiJ.(KKI. Comp•r•tlv•$ for th• stat•m•nt of finandal actltI UnrestrScl&d fund Incom? Jnd •ndowm•nts from Donations and legacies 43,447 Chadtabl¢ acllvltl•¥ Fund-raising activities 300.297 Investment income 834 Total 344,578 Expendltur• on Charltable actlvltl•• Expenditure on charitable evenl8 Administrative services P8yments lor medical rgsgarch. dlnl¢al F and new 1g¢hnologiOS Support costs 51,201 66,419 288,109 28,033 Total 433,762 NET INCOMEI{EXPENDiniREI 189,1841 Roconclllatlon of Total funds browJhl fowrd 142.076 Total fund• ¢arri•d forward 52.892 17
ALEX'S WISH NOTES TO THE FINANCIAL STATEMENTS- continued FOR THE YEAR ENDED 30 JUNE 2024 Debtors.. amounts falllng du• wlthln one ar 2024 2023 Trade debtOTS Prep8yments and wued inrne 2,165 13.978 3,2 16.083 12,979 Credltor8: amounts lalllng du• wlthln on• s•ar 2024 2023 Social security and other taxes Accruals and delerTed income 409 11,980 655 14,381 12,389 15,036 Mov•m•nt In fund• Net movement In funds At 30.6.24 At 1.7.23 Unr••trlet•d fvnd$ Unrestriclgd funds 52.892 18.940 71,832 TOTAL FUNDS 52.892 18.940 71,832 Not mov8m8nl In funds. Includ8d In the above are as loll Incoming resou$ Resources &xpend8d Mov8ment in funds unltrIct fund• Unrestrithd funds 287,081 1268,1411 18.940 TOTAL FUNDS 287.081 1268,1411 18,940 Comp•ratlv•• for mov•ment In lund• movement In funds Al 30.6.23 At 1.7.22 Unr•strfct•d fund8 Unrestricted funds 142.076 89.1841 52.892 TOTAL FUNDS 142.076 189.1841 52.892 Comp8r81ive nel movtrmenl in lund$. in¢lud811 in iho above 8fy 88 followF: Incoming Resources expended Movemgnl In funds Unrestrlcted fvnd• Unrestricted fiJnds 344,578 1433.762) 189,1841 TOTAL FUNDS 344.578 1433,762 189,1841 18
ALEX'S WISH NOTES TO THE FINANCIAL STATEMENTS- continu FOR THE YEAR ENDED 30 JUNE 2024 10. Related party dlsclosur•s Them re no relaled paty transactions for the year endgj 30 June 2024. 19
ALEX'S IMSH DETAILED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 30 JUNE 2024 2024 2023 Incom• and •ndowment8 Donatlons and l•ga¢l•s Donations 37.644 43.447 Inv•stm•nt income Deposit auount intergst 1.168 834 Charltable xtl¥ltl•• Fund-raising ac¢lvili8S 248.269 3110,297 Total Incomlng r•sourc•• 287,081 344.576 Expondllure Charltabl• actlvltt•• Annual Golf Oay Prudentlal Ridè London Annual FundraisirrfJ 8811 including cost of au.0ft pr88 Our Bu8ine55 Comrnunlty London Marathon Supercars Charity Event 'Be More Alex, fa9ular giing campaign Abseil Charity Event AGM l Annual Supporters Thank You LLJnch Miss Great Britain Fin818 Event Skydiving Events Foolb811 Event Loop Ihe Loop Challengo ¥th Aerospar Stan Hulme's Nordic Challeng8 Other sundry avenl co818 Big Give Christmas Challenge Fashion Show Sprfng Launch Grand Prix Event Kazoo Pink Ball 4,794 4,538 945 26.199 35S 2,592 4.778 481 1.272 3,774 1.025 20,807 429 3.531 6.696 783 1,145 5,009 639 2.768 448 2,218 109 150 1,088 1,153 100 626 1.247 110 914 49.842 51,201 Support ¢o•t¥ Manag•ment Wages Pensions oirice Rent Insur8nce Business D8v8lopment & NerkIng Evonl$ Postage and stationgry Promotional materials Office equipment Bookkèeping and legal fees rr8vel and subsiste Bank charges Staff Training and Welfare Computer and software costs Website and email markèts'ng Accountancy Carried foard 77.943 1.612 7,140 64,946 1,473 3,570 730 5.763 213 4,907 2.092 278 1,824 358 366 5.142 460 2,340 94,452 2.063 1.349 2,793 713 257 370 3,690 874 2.340 104.849 This pe does not fm part of the atutory finaniial statements 20
ALEX'S WISH DETAILED STATEMENT OF FINANCIAL ACTMTIES FOR THE YEAR ENDED 30 JUNE 2024 2024 2023 Manag•m•nt Brought forward 8usinès$ services 104,849 450 94,452 105.299 94,452 Other Payments for Medical Research. Clinical Post$ and New Technolcgle$ 113.1)00 288,109 Tot81 ffjsources gxpended 268.141 433,762 N•t Incom•ll•xpendltur•l 18,940 189,1841 This page does I1 form part of the stalutory financial ststements 21